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Tetrahymena thermophila are free-living, ciliated eukaryotes. Their behavioral response to stimuli is well characterized and easily
observable, since cells swim toward chemoattractants and avoid chemorepellents. Chemoattractant responses involve increased
swim speed or a decreased change in swim direction, while chemorepellent signaling involves ciliary reversal, which causes the
organism to jerk back and forth, swim in small circles, or spin in an attempt to get away from the repellent. Many food sources, such
as proteins, are chemoattractants for these organisms, while a variety of compounds are repellents. Repellents in nature are thought
to come from the secretions of predators or from ruptured organisms, which may serve as “danger” signals. Interestingly, several
peptides involved in vertebrate pain signaling are chemorepellents in Tetrahymena, including substances P, ACTH, PACAP, VIP, and
nociceptin. Here, we characterize the response of Tetrahymena thermophila to three different isoforms of nociceptin. We find that Gprotein inhibitors and tyrosine kinase inhibitors do not affect nociceptin avoidance. However, the calcium chelator, EGTA, and the
SERCA calcium ATPase inhibitor, thapsigargin, both inhibit nociceptin avoidance, implicating calcium in avoidance. This result is
confirmed by electrophysiology studies which show that 50 𝜇M nociceptin-NH2 causes a sustained depolarization of approximately
40 mV, which is eliminated by the addition of extracellular EGTA.

1. Introduction
Nociceptin/orphanin FQ (hereafter referred to as nociceptin)
is a peptide involved in vertebrate pain signaling. The
endogenous receptor for this ligand is ORL-1/NCR [1, 2].
A number of signaling pathways have been implicated in
vertebrate nociceptin signaling. A partial listing of molecules
involved in this signaling cascade would include G𝑖/𝑜 proteins
[1], neuronal nitric oxide synthase (nNOS) [3], and Erkdependent signaling [4]. In addition, signaling through the
nociceptin receptor induces a reduction in calcium influx via
P/Q-type calcium channels in rat brain [5].
Tetrahymena thermophila are free-living, unicellular
eukaryotes. While T. thermophila do not feel pain, they are
capable of sensing chemoattractants and chemorepellents in

their environment. This allows them to find food and possibly
to escape predation [6]. A recent review by Csaba [7] details
the response of T. thermophila to a number of chemoattractants and chemorepellents, including their response to
many vertebrate hormones. Indeed, T. thermophila appear
to synthesize and respond to a number of vertebrate hormones, including serotonin, melatonin, adrenocorticotropic
hormone, and insulin [7].
A number of chemorepellents which have been characterized in T. thermophila are polycationic peptides, including
lysozyme [8], the lysozyme fragment CB2 [9], PACAP [10],
and nociceptive peptides including bradykinin and substance
P [11]. Lysozyme signaling involves a calcium-based depolarization [12]. Lysozyme and PACAP appear to share a signaling
pathway [9], which involves cAMP and phospholipase C

2
[13], as well as NOS and cGMP [14]. A related peptide,
VIP, also uses these signaling pathways and cross-adapts
with lysozyme and PACAP, suggesting that Tetrahymena are
signaling through a generalized polycation receptor [15].
Nociceptin is a polycationic peptide that is commercially
available in three different isoforms. Nociceptin carries a
charge of +4 at pH 7.0, while nociceptin-NH2 carries a charge
of +5 at pH 7.0. Nociceptin-Arg14 Lys15 carries a charge of +6
at pH 7.0. Our hypothesis was that all three of the nociceptin
analogues would be chemorepellents in T. thermophila and
that more highly charged nociceptin isoforms will have a
lower EC100 in behavioral assays than isoforms which carry
a lesser charge.

2. Materials and Methods
2.1. Cell Cultures. Tetrahymena thermophila, strain B2086, a
generous gift from Hennessey [6] (SUNY Buffalo), was used
for all of the experiments. Cells were grown at 25∘ C in the
axenic medium of Dentler [16], without shaking or addition
of antibiotics. Two-day old cell cultures were used for all
behavioral assays described below.
2.2. Chemicals and Solutions. Behavioral assays were carried out in a buffer of pH 7.0 containing 10 mM Trizma
base, 0.5 mM MOPS, and 50 𝜇M CaCl2 . All repellents and
inhibitors used were dissolved in this buffer.
All nociceptin isoforms, thapsigargin, J-113397, and
EGTA, were purchased from Tocris Biosciences, Bristol, UK.
2.3. Behavioral Assays. Behavioral assays were carried out
as previously described [8, 10, 17]. Ten milliliters of T.
thermophila culture was washed by centrifugation in a clinical
centrifuge at high speed, and the pellet was reconstituted in
10 mL buffer. This wash step was repeated twice, and cells were
reconstituted in 5 mL of buffer for use in behavioral assays. To
perform the behavioral assays, 300 𝜇L of cell suspension was
transferred to the first well of a microtiter plate. Cells were
then transferred individually using a micropipette into the
second well of the microtiter plate, which contained 300 𝜇L
of buffer as a control. Cells were then transferred to a third
well containing 300 𝜇L of nociceptin. Behavior of the cells was
observed for the first 5 seconds after transfer to the third well,
and the percentage of cells exhibiting avoidance behavior was
noted. Varying concentrations of each peptide were used until
we determined the minimum concentration at which 90%
of the cells exhibited avoidance behavior (EC100 ). Each trial
represents 10 cells. A minimum of 6 trials was performed for
each data point.
Pharmacological inhibition assays were performed similar to the behavioral assays described previously. After being
washed in buffer, cells were exposed to pharmacological
agents known to block specific signaling pathways and incubated for 15 minutes to 2 hours. Cells were then transferred to
a solution containing nociceptin at EC100 and then monitored
for avoidance behavior. Each trial represents 10 cells. A
minimum of 6 trials was performed for each data point.
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Cross-adaptation assays were performed as previously
described [10, 17]. Briefly, 300 𝜇L of cells were placed into
the first well of a 3-well microtiter plate. Cells were then
individually transferred to the second well of the 3-well
microtiter plate, which contained a repellent. The cells were
allowed to adapt to this repellent for 10–15 minutes or until
cells showed baseline avoidance (an avoidance of no more
than 20%). Cells were then individually transferred to the
third well of the 3-well microtiter plate, which contained the
repellent to be tested for cross-adaptation and monitored for
avoidance behavior. Data which showed 20% or fewer cells
exhibiting avoidance was considered “baseline avoidance.”
Baseline avoidance is the number of cells in our assay which
show avoidance behavior when being transferred from one
well containing buffer to another well containing the same
buffer and usually ranges from 5 to 20%. Cells exhibiting
baseline avoidance in response to this assay were considered
to be cross-adapted. Each trial represents 10 cells. A minimum
of 6 trials was performed for each data point.
2.4. Electrophysiology. Standard one-electrode whole-cell
membrane potential recordings were recorded as the previously reported procedures in Tetrahymena thermophila
[9, 12]. The recording buffer contained were carried out
in a buffer of pH 7.0 containing 10 mM Trizma base,
0.5 mM MOPS, and 1 mM CaCl2 . Membrane potentials
were displayed on a digital oscilloscope and retained on
a chart recorder during continuous bath perfusion at a
rate of approximately 20.0 mL/min. The recording bath had
a volume of approximately 1 mL. Solutions were changed
by switching valves connected either to buffer or to the
experimental solution without changing the flow rate of the
perfusion system.

3. Results
All isoforms of nociceptin were chemorepellents in T. thermophila (Figure 1). Nociceptin, which has a charge of +4 at
our assay pH of 7.0, had an EC100 of 100 𝜇M in our behavioral
assay. Nociceptin-NH2, which has a charge of +5 under assay
conditions, had an EC100 of 50 𝜇M, while nociceptin-Arg14 Lys15 which has a charge of +6 under assay conditions had
an EC100 of 25 𝜇M. Avoidance was observed for 1–5 seconds
but was seen for as long as 10–15 minutes (not shown). After
cells acclimated to the nociceptin, they returned to forward
swimming.
Cross-adaptation assays (Table 1) show that all three isoforms of nociceptin cross-adapt with one another. However,
nociceptin-adapted cells did not cross-adapt to PACAP-38,
and PACAP-adapted cells did not cross-adapt to nociceptin.
Since all three nociceptin isoforms cross-adapted to one
another, implying a common signaling pathway, we used
50 𝜇M nociceptin-NH2 in all subsequent pharmacological
and behavioral assays.
Studies with pharmacological agents known to block
G-protein signaling, tyrosine kinase signaling, and broad
spectrum kinase activity had no effect on avoidance behavior
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Table 1: Nociceptin cross-adaptation studies. Cells were adapted to a given ligand by incubating them in that ligand for 10–15 minutes
or until avoidance behavior ceased. Cells were then moved into another ligand and were scored positively or negatively for avoidance.
Cross-adaptation with various analogues of nociceptin all show avoidance values that are at or below baseline (≤20%; [10]). However, crossadaptation with the polycationic peptide, PACAP, does not cross-adapt with nociception, implying that nociception is using a pathway that is
distinct from the previously described lysozyme/PACAP receptor [10, 15]. 𝑁 represents the number of trials conducted. Each trial consisted
of 10 cells, which were individually scored as positive or negative for avoidance.

Nociceptin
Nociceptin-NH2
Nociceptin Arg14 Lys15
PACAP 1-38

Nociceptin
9.2 ± 8.2
𝑁 = 13
5 ± 7.5
𝑁=9
3.3 ± 5.8
𝑁=6
97.5 ± 4.6
𝑁=8

Nociceptin-NH2
5 ± 8.3
𝑁=6
16.9 ± 12.2
𝑁=8
13.3 ± 12.1
𝑁=6
100 ± 0
𝑁 = 10

PACAP 1-38
96.6 ± 5.8
𝑁=6
100 ± 0
𝑁=6
91.25 ± 9.9
𝑁=8
13.3 ± 5.8
𝑁=6

100
Cells showing avoidance (%)

100
Cells showing avoidance (%)

Nociceptin Arg14 Lys15
0±0
𝑁=6
14.5 ± 12.4
𝑁 = 12
16.6 ± 16.3
𝑁=6
100 ± 0
𝑁 = 10

80
60
40
20

80
60
40
20
0

0

0.1

1

10

100

1000

[Nociceptin] (𝜇M)

0.1

1

10

100

1000

10000

[Inhibitor] (𝜇M)

Figure 1: Nociceptin is a chemorepellent in Tetrahymena thermophila. Nociceptin (closed circles), nociceptin-NH2 (closed
squares), and nociceptin-Arg14 Lys15 (closed diamonds) all caused
avoidance in Tetrahymena thermophila. The EC100 of each compound was correlated with its charge. Nociceptin, which has a net
charge of +4, had an EC100 of 100 𝜇M. Nociceptin-NH2, which has
a net charge of +5, had an EC100 of 50 𝜇M. Finally, nociceptinArg14 Lys15 , which had a net charge of +6, had an EC100 of 25 𝜇M.
𝑁 ≥ 6. 𝑁 represents the number of trials conducted. Each trial
consisted of 10 cells, which were individually scored as positive or
negative for avoidance.

Figure 2: Calcium chelators inhibit the behavioral response to
50 𝜇M nociceptin-NH2 in Tetrahymena thermophila. EGTA (closed
circles) reduces avoidance to 20% (near baseline) at a concentration
of 50 𝜇M. The IC50 of EGTA is approximately 7.5 𝜇M. Thapsigargin
(open triangles) reduced avoidance by 50% at a concentration of
100 𝜇M; however, increasing the concentration to 300 𝜇M did not
cause a significant decrease in avoidance beyond that seen with
100 𝜇M thapsigargin. 𝑁 ≥ 6. 𝑁 represents the number of trials
conducted. Each trial consisted of 10 cells, which were individually
scored as positive or negative for avoidance.

in T. thermophila (Table 2). However, studies with the calcium
chelator, EGTA, and the SERCA ATPase inhibitor, thapsigargin, both affected nociceptin avoidance (Figure 2). A concentration of 50 𝜇M EGTA was sufficient to reduce avoidance to
a baseline avoidance of 20%. Thapsigargin, however, never
reduced avoidance to baseline under the conditions of our
assay. The highest concentration of thapsigargin we were able
to achieve in our assay was 300 𝜇M. Thapsigargin reduced
avoidance by 50% at a concentration of 100 𝜇M; however,
increasing the concentration to 300 𝜇M did not decrease
avoidance beyond that seen with 100 𝜇M thapsigargin.
Whole-cell electrophysiology studies indicate that
nociceptin-NH2 is a depolarizing signal in T. thermophila

(Figure 3). A nociceptin-NH2 concentration of just 5 𝜇M
was sufficient to elicit a depolarization of approximately
20 mV, though this concentration does not cause
behavioral avoidance above baseline levels in Tetrahymena
(Figures 3(a) and 1). Fifty 𝜇M nociceptin-NH2, which is the
EC100 for behavioral avoidance in Tetrahymena, elicited a
depolarization of approximately 40 mV (Figure 3(b)). The
depolarization produced by 50 𝜇M nociceptin-NH2 was
eliminated by the addition of 1 mM EGTA to the external
medium (Figure 3(c)).
J-113397, a competitive inhibitor of the human nociceptin receptor, inhibited the behavioral response to 50 𝜇M
nociceptin-NH2 in Tetrahymena thermophila when applied
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1 mM EGTA

10 mV

5 𝜇M
nociceptin-NH2 Buffer
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Figure 3: Nociceptin-NH2 is a depolarizing signal in Tetrahymena thermophila. (a) 5 𝜇M nociceptin-NH2 causes a depolarization of
approximately 20 mV, though this concentration does not often provoke a behavioral response in Tetrahymena. (b) 50 𝜇M nociceptinNH2 causes a depolarization of approximately 40 mV. This concentration is the EC100 for behavioral avoidance in Tetrahymena. (c) The
depolarization produced by 50 𝜇M nociceptin-NH2 is eliminated by the addition of 1 mM EGTA to the external medium, implying that
calcium is involved in the depolarization.
Table 2: Pharmacological inhibitors which act on G-protein mediated receptor pathways and tyrosine kinase pathways do not significantly
impact nociception avoidance. 𝑁 represents the number of trials conducted. Each trial consisted of 10 cells, which were individually scored
as positive or negative for avoidance.
Pharmacological inhibitor
Control
50 𝜇M RpcAMPs
1 mM GDP-𝛽-S
1 𝜇M U-73122
1 𝜇M U-73345
10 𝜇M calphostin C
1 mM 1400 W
100 𝜇M tyrphostin 47
100 𝜇M AG126
150 𝜇M SU 6668
300 𝜇M apigenin
3 mM H-9

Pathway inhibited

Percentage of cells avoiding nociceptin

𝑁

None
Adenylyl cyclase
G-proteins
Phospholipase C
Inactive analogue of U-73122
Protein kinase C
NOS
Receptor tyrosine kinases
Map kinase pathway
Receptor tyrosine kinases
Protein kinases
Protein kinases

94.28 ± 5.34
96.67 ± 5.16
100.0 ± 0.0
97.78 ± 4.40
96.67 ± 5.16
96.0 ± 5.0
96.0 ± 5.0
92.5 ± 9.57
96.0 ± 6.99
91.66 ± 4.08
91.2 ± 6.4
96.6 ± 5.1

8
6
6
9
6
10
10
6
10
6
8
6

extracellularly (Figure 4). Baseline avoidance to nociceptin
was achieved by the addition of 50 𝜇M of J-113397.

4. Discussion
Our results confirmed our hypothesis that all three nociceptin isoforms tested would serve as chemorepellents in
T. thermophila (Figure 1). In addition, the EC100 of each

compound was correlated with the charge, with the most
highly charged isoform having the lowest EC100 , although all
of the EC100 values were in a similar range. The correlation
of lower EC100 values with a higher charge is consistent
with what we have seen using other charged peptides in T.
thermophila. For example, when we have used various peptides derived from ACTH, the more highly charged peptides
caused avoidance at lower concentrations than did the less

International Journal of Peptides

5

Cells showing avoidance (%)

100
80
60
40
20
0

0.1

1

10

100

[J113397] (𝜇M)

Figure 4: J-113397, a competitive inhibitor of the human nociceptin
receptor, inhibits the behavioral response to 50 𝜇M nociceptin-NH2
in Tetrahymena thermophila when applied extracellularly. The IC50
of this compound is approximately 5 𝜇M. 𝑁 ≥ 6. 𝑁 represents the
number of trials conducted. Each trial consisted of 10 cells, which
were individually scored as positive or negative for avoidance.

highly charged peptides [11]. In addition, our previous studies
with PACAP and VIP [15] show that PACAP is effective at
causing avoidance at a 1000-fold lower concentration than
VIP, though presumably acting through the same receptor
and/or signaling pathway. The isoform of PACAP that we
used in the 2003 study, PACAP-38-NH2, has a net charge
of +11 at pH 7.0, while VIP has a net charge of just +4 at
the same pH. While factors other than charge are certainly
involved in the interaction between these peptides and their
putative receptor, it is highly probable that charge is playing
a role in these interactions, possibly by increasing the affinity
of ligand for its receptor. In the case of nociceptin, the charge
differences were relatively small as were the differences in
EC100 .
Cells acclimated to nociception within 10–15 minutes
of first being exposed to it (not shown). All isoforms of
nociceptin were cross-adapted to one another, indicating that
all forms of nociceptin were using the same receptor and/or
signaling pathway. This is similar to what has previously
been shown for lysozyme [8] and PACAP/VIP [15]. Since
PACAP, lysozyme, and VIP appear to share a common
receptor [10, 15], we cross-adapted cells to nociceptin and
PACAP to determine whether nociceptin was using the same
receptor/signaling pathway as the three previously studied
polycationic ligands. As Table 1 shows, PACAP-adapted cells
did not cross-adapt to nociceptin and nociceptin-adapted
cells did not cross-adapt to PACAP. This indicates that
nociceptin signals through a pathway that does not involve
the previously described polycation receptor.
The previously studied PACAP response appears to be
mediated through a G-protein-coupled receptor which uses
adenylyl cyclase, phospholipase C, and nitric oxide synthase
[10, 13–15]. In order to further ascertain whether nociceptin
was using a separate signaling pathway, we used pharmacological inhibitors to block G-protein-linked receptors and

associated pathways. None of these inhibitors blocked avoidance to nociceptin (Table 2), giving further evidence that the
previously described polycation receptor is not being used
in nociceptin signaling. This also differs from the vertebrate
nociceptin receptor, which signals through G𝑖/𝑜 proteins [1].
Since a tyrosine kinase has been implicated in GTP
signaling in T. thermophila [18] as well as insulin signaling
[19], we also tested a battery of protein kinase and tyrosine
kinase inhibitors to determine whether nociceptin signaling
would be inhibited. None of these inhibitors affected nociceptin signaling (Table 2). Interestingly, genomic studies of
Tetrahymena [20] show no evidence of the presence of a
tyrosine kinase in this organism.
Since a calcium-based depolarization is elicited by the
addition of lysozyme [12] as well as the lysozyme fragment, CB2 [8], to T. thermophila, we wished to determine
whether calcium was involved in nociceptin signaling in this
organism. Studies with the external calcium chelator, EGTA
(Figure 2) indicated that extracellular calcium was necessary
for behavioral avoidance to nociceptin, since concentrations
of EGTA above 50 𝜇M reduced avoidance down to baseline.
Baseline avoidance in this organism is determined by counting the number of cells that show avoidance behavior when
transferred from one well of buffer to another well of the
same buffer [10]. The SERCA ATPase inhibitor, thapsigargin,
was used to determine whether internal calcium stores were
required in order for avoidance to occur. As seen in Figure 2,
exposure of cells to 100 𝜇M thapsigargin reduced avoidance
by approximately 50%. However, the avoidance response was
not completely inhibited, indicating that while intracellular
calcium may play a role in avoidance, lack of intracellular
calcium stores depleted by thapsigargin may be partially
compensated for by allowing extracellular calcium into the
cytosol. Notably, the thapsigargin concentration used in this
study was much higher than what we used in a previous
study [18], in which only 1 nM thapsigargin was necessary in
order to block the behavioral response to GTP. This is further
evidence that extracellular calcium is primarily responsible
for nociceptin avoidance. Calcium is not necessary for avoidance to all peptides, however, since avoidance of netrin-1,
semaphorin 3C, and fragments of ACTH is unaffected by
addition of either EGTA or thapsigargin [11].
Whole-cell electrophysiology studies indicate that nociceptin causes a depolarization in T. thermophila (Figure 3),
even at concentrations that normally do not cause a behavioral response in this organism (Figures 3(a) and 1). When
the EC100 of nociceptin-NH2 was used, the amplitude of
the depolarization increased (Figure 3(b)). Finally, we were
able to remove the depolarization by the addition of EGTA
to the external medium (Figure 3(c)), implying that calcium
is involved in the depolarization. This is similar to the
previously described responses to lysozyme [12] and the
lysozyme fragment, CB2 [9].
The involvement of calcium in nociceptin avoidance in
T. thermophila is rather different from the human response
to nociceptin, which involves closing calcium channels
[5]. However, we did use J-113397, which is a competitive
inhibitor of the human nociceptin receptor [21], in order to
determine if it could also block T. thermophila avoidance

6
to nociceptin. As shown in Figure 4, 50 𝜇M J-113397 was
effective in reducing avoidance to baseline. This drug had no
effect on avoidance to ACTH fragments (data not shown),
suggesting that the response was specific to nociceptin. While
we have not identified the receptor or signaling pathway that
nociceptin is using in T. thermophila, these data suggest that
there may be commonalities between the human nociceptin
receptor and a possible nociceptin-binding protein in T.
thermophila.
In summary, we have shown that nociceptin is a chemorepellent in Tetrahymena which elicits a depolarization. It
does not act through the previously described polycation
receptor nor does it signal through a G-protein-mediated
receptor like the vertebrate nociceptin receptor. However,
the J113397 studies imply that Tetrahymena may possess
some type of receptor that shares binding characteristics
with the human nociceptin receptor. Further studies may
help elucidate the signaling mechanisms used in nociceptin
avoidance in T. thermophila. If the receptor is identified,
comparisons between the human nociceptin receptor and the
unknown nociceptin-sensing mechanism in T. thermophila
would be instructive.

5. Conclusions
The vertebrate signaling peptide, nociceptin, is a chemorepellent in Tetrahymena thermophila. The effectiveness of
signaling is impacted by the charge of the nociceptin isoform,
with more highly charged forms of nociceptin requiring
lower concentrations to signal effectively. Nociceptin does
not signal through the previously described polycation receptor of Tetrahymena thermophila nor does it signal through
a G-protein-linked receptor, as it does in humans. However,
nociceptin avoidance in Tetrahymena thermophila is blocked
by addition of J-113397, a competitive inhibitor of the vertebrate nociceptin receptor. This suggests that the vertebrate
nociceptin receptor and its analog in Tetrahymena may
share common binding characteristics. Finally, nociceptin
signaling provokes a depolarization, which pharmacological
studies suggest may be caused by an influx of calcium.
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PACAP: Pituitary adenylyl cyclase activating
polypeptide
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